Table 2.
Examples of on-going clinical trial with novel therapeutic nanoparticles conjugated with different types of drugs.
| Nanoparticle Category | NCT | Status | Clinical phase | Binding molecule | Challenges | Questions |
|---|---|---|---|---|---|---|
| Gold | NCT03020017 | Recruiting | Early Phase I | siRNA (Spherical Nucleic Acid) | Targeting BCL2L12 gene in glioblastoma | Safety to be determined |
| NCT01420588 | Recruiting | n/a | Na-Nose (chemical nanosensors) | Discrimination between gastric lesions | Effectiveness to be demonstrated | |
| Liposomal | NCT01455389 | Recruiting | Phase I–II | FUS-1 and Erlotinib | Transfer FUS-1 gene into lung cancer cells | Efficacy and dosing to be determined |
| NCT00734682 | Completed | Phase I | Liposomal Irinotecan | To treat patients with recurrent high-grade gliomas | Safety and dosing to be defined | |
| (SMARTICLES©) | NCT02716012 | Recruiting | Phase I | MTL-CEBPA (double stranded RNA) | To activate the CEBPA gene in advanced liver cancer | Toxicity profile and dose for phase II to be determined |
| NCT02631733 | Recruiting | Phase I | Liposomal Irinotecan plus Veliparib | To test this combination in solid tumors | Safety and dosing to be determined | |
| Dendrimers | NCT03255343 | Recruiting | Phase I | ImDendrim o [188Re] rhenium complex | To evaluate responder in Stage IV liver cancer | Non-removal nanodevice |
| Carbon nanotubes | NCT02123407 | Unknown | Phase III | Harvesting lymph nodes | Guidance to lymph node dissection in gastric cancer surgery | Insufficient evidence to date |
| NCT03350945 | Not yet recruiting | n/a | None | To better localize tumor and lymph nodes mapping in the colorectal surgery | Safety, efficacy and economy efficiency To be determined | |
| Other NPs categories | ||||||
| Sugar molecule (CRLX101) | NCT02769962 | Recruiting | Phase I–II | Camptothecin plus olaparib | To test in small cell lung cancer | Toxicity profile to be determined |
| Magnetic NPs | NCT02033447 | Completed | Early Phase I | None | To treat prostate cancer with thermoablation | Retention and/or maintenance in the prostate |
| Polysiloxane Gd-Chelates | NCT03308604 | Not yet recruiting | Phase I | With chemo-radiation and brachytherapy | To escalate dose in cervical cancer | Dosing to be determined |
| Radio-enhancer (NBTXR3) | NCT02805894 | Recruiting | Phase I–II | Activated by radiotherapy | To treat locally-advanced prostate cancer | Efficacy to be demonstrated |
NCT: number of clinical trial (reference of clinicaltrials.gov); siRNA: short interfering RNA; n/a: not applicable; NPs: nanoparticles.